FocalTherics Q2 HIFU Revenue Jumps 34-39%, Sheds Legacy Units
FOCL has more than doubled off its 52-week low of $1.26.
Summary
FocalTherics reported preliminary Q2 2026 HIFU segment revenue of $12.7M-$13.2M, up 34-39% year-over-year, with gross margins expanding to 54-56%. The company is exiting its ESWL and Distribution businesses, classifying them as discontinued operations — a strategic shift that sharpens focus on the high-growth robotic focal therapy platform. Cash stood at $21.5M as of June 30. This follows the June 30 launch of the endometriosis program and the August 11 public offering filing; the strong top-line growth and margin expansion may offset dilution concerns. Full Q2 results and a conference call are set for August 13 after market close.
At the time of this announcement, FOCL was trading at $5.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $227.9M. The 52-week trading range was $1.26 to $6.40. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.